Mind Medicine (MindMed) Inc
F:MMQ
Mind Medicine (MindMed) Inc
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company is headquartered in New York City, New York. The company went IPO on 2015-05-04. The firm is engaged in developing products to treat brain health disorders. The company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM-120 is a pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Mind Medicine (MindMed), Inc. operates as clinical stage biopharmaceutical company, which engages in developing novel product candidates to treat brain health disorders. The company is headquartered in New York City, New York. The company went IPO on 2015-05-04. The firm is engaged in developing products to treat brain health disorders. The company is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM-120 is a pharmaceutically optimized form of lysergide D-tartrate that the Company is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).
Clinical Milestones: Definium expects three pivotal Phase III readouts in 2026 for its lead candidate DT120 ODT, targeting generalized anxiety disorder (GAD) and major depressive disorder (MDD), with the first data from the Emerge MDD study due in late Q2.
Strong Enrollment: Enrollment is robust and ahead of expectations in key trials: Emerge (MDD) is fully enrolled, Voyage (GAD) is about 80% enrolled and nearing completion, and Ascend (MDD) has begun site activation.
Statistical Power: The interim blinded sample size re-estimation for Voyage found no increase in sample size needed, with observed parameters suggesting over 99% power to detect efficacy.
Financial Position: Definium ended 2025 with $411.6 million in cash, cash equivalents and investments, up from $273.7 million, and projects its cash runway extends into 2028.
Increased Spending: R&D expenses rose to $117.7 million (from $65.3 million), and G&A to $48.6 million (from $38.6 million), mainly due to late-stage programs and commercial readiness.
Commercial Preparation: The company has built out its commercial leadership and infrastructure, focusing on delivering a "white glove" provider experience and preparing for rapid product launch if approved.
Durability & Differentiation: Management highlighted best-in-class potential for DT120 based on both magnitude and durability of clinical effect, with Phase II data showing strong efficacy on anxiety and depression scales.
